Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
World Health Organization. Obesity and overweight. (2024).Non-Communicable Disease Risk Factor Collaboration. Worldwide trends in underweight and obesity from 1990 to...
:quality(85):upscale()/2024/12/04/799/n/1922153/b75c544667509b4fd65d97.33975776_.jpg "Harms of Unsolicited Skin-Care Advice")
